Commercial momentum builds across both platform pillars
Filed with ASX · · 10 pages · English
Summary by 6ix AI
Control Bionics Ltd. provides a business update on its commercial progress across its Assistive Technology and NeuroTechnology Solutions pillars, highlighting significant developments in various markets. The company reports the shipment of its first NextLevel tablets and the expansion of its NeuroStrip commercial footprint to multiple organizations across several countries. Control Bionics anticipates further growth as it scales its wholesale channels in the US and establishes distribution partnerships in Germany and the UK. The update includes clinical validation findings from Japan, demonstrating the effectiveness of NeuroStrip in assessing muscle activity in rehabilitation settings.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Control Bionics
- Completion of Placement
- Pause in Trading
- Commercial Momentum Presentation
- German Statutory Reimbursement Listing for NeuroNode
- Joint venture with NextLevel Assistive Technology
Later from Control Bionics
- US FDA Registration and Device Listing for NeuroStrip
- NeuroStrip secures MHRA registration
- Medicare Billing Code Secured for NextLevel Speech Devices
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Control Bionics into a list and get an email when it puts out news.
Follow Control Bionics